SOURCES SOUGHT
Q -- Profiling of 40 optimized small molecule kinase inhibitors versus 359 wild-type kinases in 10-dose IC50 determining assays
- Notice Date
- 1/14/2015
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SBSS-15-090
- Archive Date
- 2/13/2015
- Point of Contact
- Megan Ault,
- E-Mail Address
-
megan.ault@nih.gov
(megan.ault@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Institutes on Drug Abuse, Station Support Simplified Acquisitions, Introduction: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. Background: Small molecules can have a multitude of activities and it is often difficult to understand which target of a small molecule is responsible for an established outcome. For instance, the small molecule nilotinib is stated to be a BCR-Abl inhibitor. However, its activity versus other kinase targets including cKit are the reason this drug has clinical activity versus non-BCR-Abl expressing cancers like GIST. Unfortunately, it is often difficult to unambiguously define the contributing versus non-contributing pharmacological actions of small molecules (kinase inhibitors, in particular, are difficult to understand). Recently, a method that utilized a regularized regression mathematical model that relies upon kinase expression data and a detailed knowledge of each small molecules polypharmacology within the kinome to deconvolute the targets of interest from the ‘passenger' targets. In order to fully apply this method reliable activity data needs to be collected for a collection of known kinase inhibitors. Several reports have been published demonstrating that these datasets can be generated and in this procurement we aim to establish a non-redundant set of activities for 40 additional kinase inhibitors. Concomitantly we will be defining unambiguous phenotypes for this collection in several biologically defined assay systems. Once agents are established that have activity and the key targets are defined the regularized model will be applied to define the contributing versus the non-contributing targets.. Purpose and Objectives: This order provides a full kinome profile for 40 established small molecule kinase inhibitors. Project requirements: The contractor shall provide the selectivity data for the 40 kinase inhibitor collection versus a minimum of 359 wild-type kinases using standard methods (for instance, the incorporation of radiolabeled phosphate from [gamma-32P]ATP into an established peptide or protein substrate). A minimum of a 10-dose complete response curve should be utilized to establish an unambiguous IC50 value for each agent versus each kinase. The contractor shall provide a full kinome profile of the 10-dose IC50 values established for 40 kinase inhibitors versus 359 wild-type kinases utilizing standard and validated assays. Anticipated period of performance: four (4) weeks after receipt of order. Capability statement /information sought: Interested organizations must provide clear and convincing documentation of their capability of providing the item(s) specified in this notice. Interested organizations that believe they possess the ability to provide the required must submit specific documentation of their ability to meet each of the project requirements to the Contract Specialist. Interested organizations must provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested organizations are required to identify their type of business, applicable North American Industry Classification System Code, and size standards in accordance with the Small Business Administration. The Government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. All capability statements sent in response to this Sources Sought Notice must be submitted electronically (via email) to Megan Ault, Contract Specialist, at megan.ault@nih.gov in MS Word format by or before the closing date of this announcement. All responses must be received by the specified due date and time in order to be considered. The response must be received on or before January 29, 2015 by11:00 AM (EDT). Note: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. The solicitation release date is pending. The Government intends to negotiate a fixed-price purchase order. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/HHS-NIH-NIDA-SSSA-SBSS-15-090/listing.html)
- Record
- SN03616228-W 20150116/150114234452-8b92947786239717708f6146bc7a5ff0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |